| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K04800985 | CTRPv2 | pan-cancer | AAC | 0.053 | 0.2 |
| mRNA | BRD-K16147474 | CTRPv2 | pan-cancer | AAC | -0.056 | 0.2 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | 0.073 | 0.2 |
| mRNA | Tipifarnib | GDSC1000 | pan-cancer | AAC | -0.052 | 0.2 |
| mRNA | CHIR-99021 | CTRPv2 | pan-cancer | AAC | -0.047 | 0.2 |
| mRNA | GW 441756 | GDSC1000 | pan-cancer | AAC | 0.052 | 0.2 |
| mRNA | KPT185 | CTRPv2 | pan-cancer | AAC | -0.054 | 0.2 |
| mRNA | BRD-A05715709 | CTRPv2 | pan-cancer | AAC | -0.079 | 0.2 |
| mRNA | S-Trityl-L-cysteine | FIMM | pan-cancer | AAC | 0.24 | 0.2 |
| mRNA | carboplatin:etoposide (40:17 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.041 | 0.2 |